Sclero: Evaluation of Bone Mineral Density in Patients with Systemic Sclerosis (SSc), during Treatment with Bosentan (Preliminary Report) - Sclero

Jump to content

Page 1 of 1
  • You cannot start a new topic
  • You cannot reply to this topic

Evaluation of Bone Mineral Density in Patients with Systemic Sclerosis (SSc), during Treatment with Bosentan (Preliminary Report)

#1 User is offline   Jeannie McClelland 

  • Senior Gold Member
  • PipPipPipPipPipPipPipPipPipPip
  • View gallery
  • Group: ISN Administrators
  • Posts: 1,121
  • Joined: 11-December 08
  • Location:in the Rocky Mountains of the USA

Posted 04 November 2009 - 08:46 AM

Evaluation of Bone Mineral Density in Patients with Systemic Sclerosis (SSc), during Treatment with Bosentan (Preliminary Report). Despite small number of patients, the results of our study seem to indicate that in SSc patients, the use of bosentan (for management of pulmonary arterial hypertension and prevention of ischemic digital ulcers) should not determine significant decrease of bone mineral density. On the contrary, in this study we have observed that bosentan stabilizes pulmonary artery PA systolic pressure and pulmonary function tests in SSc patients. S. Bellissimo. (SAT0234). EULAR 2009. (Also see: Bone Density and Bosentan)


These items were posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information
Jeannie McClelland
ISN Sclero Forums Manager
ISN Assistant News Guide
International Scleroderma Network(ISN)
Page 1 of 1
  • You cannot start a new topic
  • You cannot reply to this topic